NEXIMMUNE INC
Compare this stock
NEXI Stock Report Card
$
25%
Performance
Score:
10/100
NEXI returned -75.26% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
25/100
NEXI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
Earnings
Score:
49/100
NEXI has missed earnings 2 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 15 quarters, NEXI has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
38/100
NEXI has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.
NEXIMMUNE INC Summary
Healthcare
Biotechnology
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
NEXI scored poorly on our reportcard. Here are some similar companies and how they performed.
